AR and prostate cancer: The CTC counts obtained with CellCollector could also be tested in metastatic castration-sensitive prostate cancer patients (mCSPC) as biomarkers for evaluation of the treatment with androgen-receptor-axis-targeted (ARAT) therapy compared with docetaxel to improve the outcome in mCSPC patients [39,40].